Gastroesophageal Junction Cancer Overview
Learn About Gastroesophageal Junction Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Duke Cancer Center
Hope Uronis is an Oncologist in Durham, North Carolina. Dr. Uronis is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. Her top areas of expertise are Gastroesophageal Junction Cancer, Colorectal Cancer, Pancreatic Cancer, Stomach Cancer, and Pancreaticoduodenectomy. Dr. Uronis is currently accepting new patients.
Rhode Island Hospital
Howard Safran is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Safran is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Pancreatic Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, Stomach Cancer, and Pancreaticoduodenectomy.
Eric Van Cutsem practices in Leuven, Belgium. Mr. Van Cutsem is rated as an Elite expert by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Colorectal Cancer, Gastroesophageal Junction Cancer, Stomach Cancer, Hepato-Pancreato-Biliary Surgery, and Endoscopy.
Summary: This study is a single-arm study aimed at evaluating the efficacy and safety of Iparomlimab and Tuvonralimab Injection combined with apatinib and irinotecan hydrochloride in the treatment of advanced alpha-fetoprotein gastric cancer (AFPGC) that progresses from first-line PD-1 combined with chemotherapy. The study enrolled patients with advanced gastric cancer and gastroesophageal junction cancer ...
Summary: The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.


